Sparsentan Bests Irbesartan for Rare, Progressive Kidney Disease
(MedPage Today) -- LONG BEACH, Calif.--Sparsentan (Filspari) led to more complete and partial remissions of focal segmental glomerulosclerosis (FSGS) compared with irbesartan (Avapro), the phase III DUPLEX trial showed.
Over the course of...